The shares of Cardinal Health, Inc. (NYSE:CAH) has been pegged with a rating of Mkt Perform by Leerink Partners in its latest research note that was published on November 16th, 2018. Leerink Partners wasn’t the only research firm that published a report of Cardinal Health, Inc., with other equities research analysts also giving their opinion on the stock. Leerink Partners advised investors in its research note published on April 24th, 2018, to Outperform the CAH stock. The stock had earned Buy rating from Argus when it published its report on April 2nd, 2018. The stock was given Equal Weight rating by Barclays in its report released on March 8th, 2018, the day when the price target on the stock was placed at $74. BofA/Merrill was of a view that CAH is Underperform in its latest report on February 27th, 2018. Evercore ISI thinks that CAH is worth In-line rating. This was contained in the firm’s report on January 5th, 2018.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 14 believe it has the potential for further growth, thus rating it as Hold while 1 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $55.57. The price of the stock the last time has raised by 14.40% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 53.34.
The shares of the company dipped by -2.01% during the trading session on Tuesday, reaching a low of $54.41 while ending the day at $55.07. During the trading session, a total of 5.15 million shares were traded which represents a -40.21% decline from the average session volume which is 3.67M shares. CAH had ended its last session trading at 56.20. Cardinal Health, Inc. currently has a market cap of $16.46B while its P/E earnings growth sits at 0.12, with a beta of 0.92. Cardinal Health, Inc. debt-to-equity ratio currently stands at 1.52, while its quick ratio hovers at 0.50. CAH 52-week low price stands at $48.14 while its 52-week high price is $75.75.
The company in its last quarterly report recorded $1.29 earnings per share which is above the $1.08 predicted by most analysts. The Cardinal Health, Inc. generated $35,213.00 million in revenue during the last quarter, which is slightly higher than the $33,654.10 million predicted by analysts. In the second quarter last year, the firm recorded $1.01 earnings per share. Compared to the same quarter last year, the firm’s revenue was up by 21.71%. Cardinal Health, Inc. has the potential to record -0.52 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Goldman published a research note on October 11th, 2018 where it informed investors and clients that State Street Corporation (NYSE:STT) is now rated as Buy. Leerink Partners also rated STT as Upgrade on April 24th, 2018, with its price target of $9 suggesting that STT could surge by 24.05% from its current share price. Even though the stock has been trading at $73.15/share, analysts expect it to surge higher by -7.30% to reach $89.28/share. It started the day trading at $72.85 and traded between $67.55 and $67.81 throughout the trading session.
A look at its technical shows that STT’s 50-day SMA is 75.79 while its 200-day SMA stands at 90.76. The stock has a high of $114.27 for the year while the low is $65.81. The company’s P/E ratio currently sits at 9.76, while the P/B ratio is 1.22. The company’s average trading volume currently stands at 2.91M shares, which means that the short-interest ratio is just 1.27 days. Over the past seven days, the company moved, with its shift of -6.73%. Looking further, the stock has dropped -22.29% over the past 90 days while it lost -31.84% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. T Rowe Price Associates Inc bought more STT shares, increasing its portfolio by +9.75% during the last quarter. This move now sees T Rowe Price Associates Inc purchasing 2,575,640 shares in the last quarter, thus it now holds 28,983,964 shares of STT, with a total valuation of $1,992,647,525. Massachusetts Financial Services meanwhile bought more STT shares in the recently filed quarter, changing its stake to $1,920,499,281 worth of shares. The Vanguard Group Inc followed the path by increasing its STT portfolio by +3.64% in the quarter. This means that The Vanguard Group Inc bought 900,824 shares in the last quarter and now controls 25,618,619 shares of the STT stock, with the valuation hitting $1,761,280,056.
Similarly, BlackRock Fund Advisors increased its State Street Corporation shares by +2.58% during the recently filed quarter. After buying 387,312 shares in the last quarter, the firm now controls 15,406,879 shares of State Street Corporation which are valued at $1,059,222,931. In the same vein, Longview Partners LLP increased its State Street Corporation shares by during the most recent reported quarter. The firm bought 3,230,396 shares during the quarter which increased its stakes to 11,202,851 shares and is now valued at $770,196,006. Following these latest developments, around 0.30% of State Street Corporation stocks are owned by institutional investors and hedge funds.